Issue 2/2010
Content (9 Articles)
Additive Effect of TAK-491, a New Angiotensin Receptor Blocker, and Pioglitazone, in Reducing Myocardial Infarct Size
Yumei Ye, Kyle T. Keyes, Chong F. Zhang, Jose R. Perez-Polo, Yu Lin, Yochai Birnbaum
Granulocyte-colony Stimulating Factor Treatment of Chronic Myocardial Infarction
Ruy A. N. Louzada, Patricia F. Oliveira, Joao Paulo A. Cavalcanti-de-Albuquerque, Leandro Cunha-Carvalho, Marcelo R. Baldanza, Taís H. Kasai-Brunswick, Regina C. S. Goldenberg, Antonio C. Campos-de-Carvalho, Joao P. S. Werneck-de-Castro
Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure
Yuliy Y. Chirkov, Michele De Sciscio, Aaron L. Sverdlov, Sue Leslie, Peter R. Sage, John D. Horowitz
Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment?
Seul-Ki Jeong, Young I. Cho, Marc Duey, Robert S. Rosenson
Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial
Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul
A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg
Cheol Whan Lee, Sang-Hong Baek, Taek-Jong Hong, Young-Jin Choi, Young-Jo Kim, Tae-Hoon Ahn, Sang-Hyun Ihm, Jang-Ho Bae, Soon-Jun Hong, Doo-Il Kim, Young-Keun Ahn, Seung-Ho Hur, Dae-Gyun Park, Dong-Ju Choi, Seung-Uk Lee, Bum-Soo Kim, Kyu-Hyung Ryu, Yang-Soo Jang, Sang-Hoon Lee, Ki-Bae Seung, Hyo-Soo Kim